Cosmetic matrikine peptide
Matrixyl Synthe'6
Matrixyl Synthe'6 is Sederma's trade name for a topical palmitoyl tripeptide-38 product with a manufacturer-stated use level of 2%; none of the sources gathered gives a half-life, while the app lists 4 hours.1
Matrixyl Synthe'6 after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.
Drawn from the half-life in the app's model, ~4 h. The model's figures
- Compound
- Matrixyl Synthe'6
- Symbol
- MS6
- Family
- Cosmetic and copper peptides
- Parts
- 11
- References
- 6
- Checked
- Last reviewed . Sources are listed below.
Overview
Matrixyl Synthe'6 is a cosmetic ingredient made by Sederma, a member of Croda International, and its brochure describes the active as a matrikine-mimetic peptide, Palmitoyl-Lysyl-Dioxymethionyl-Lysine.1 The ingredient is supplied as a mixture whose INCI name is Glycerin, Aqua, Hydroxypropyl Cyclodextrin, Palmitoyl Tripeptide-38.2 The brochure states that it is water soluble and that the recommended pH is 3 to 9.1 The route is topical, applied in creams and serums in the studies described below.1,3
The app grades the evidence as moderate and its own note describes it as mostly manufacturer-associated. The human data read for this compound are one manufacturer-run split-face study of 25 women reported in a Sederma brochure, an open-label serum study of 35 women funded by Alumier, an open-label study of 37 women using a multi-ingredient moisturizer, and a study of 32 women using a multi-ingredient serum whose PubMed record names no comparator.1,3,6,5 A PubMed query for "palmitoyl tripeptide-38" returned 3 records, all of multi-ingredient products, and no peer-reviewed trial of the peptide on its own was identified.
How it works
Sources in this part
The brochure says the peptide is built on the lysine-methionine-lysine (KMK) sequence, "a sequence found naturally in matrix proteins", specifically in collagen VI and laminins, with the methionine in a dioxygenated form.1 Sederma describes it as stimulating "the synthesis of six major molecules (hyaluronic acid," collagen I, III and IV, laminins and fibronectin, together with the chaperone protein HSP47.1 These mechanism data are in vitro and ex vivo results from the manufacturer, not measurements in people.1 The brochure reports, for the peptide at 5 ppm (stated as equivalent to 2% of the product), increases in cell and explant tests of collagen I of +111% (fibroblasts) and +37% (explants), collagen III +104%, fibronectin +59%, HSP47 +123%, collagen IV +42%, laminins +75% and hyaluronic acid +174%.1 The brochure's own earlier table also reports that the non-oxygenated version of the peptide gave results that were not statistically significant for fibronectin and collagen IV at 4 and 6 ppm, in contrast with the dioxygenated form.1 A journal paper on a serum with 5 ppm of the peptide repeats the six-molecule statement and cites "Extensive in vitro and ex vivo (human skin explants) experiments", and, on its isotropy results, says further exploration of the underlying mechanisms of redressing the ECM "is ongoing".3 That paper's authors are consultants for the serum's maker, so it is not independent of a commercial interest, and it does not itself measure matrix molecules in skin.3 Cell and explant results are not measurements of collagen or hyaluronic acid in the skin of people who apply a cream.
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~4 h
- Bioavailability
- 95%
- Typical dose
- 2–4%
- Route
- Topical
- Time to peak
- ~0.5 h
Sources in this part
The app's figures are a half-life of 4 hours, bioavailability of 95%, a time to peak of 0.5 hours and a one-compartment model, and none of the sources gathered reports a blood level, half-life, bioavailability or time to peak for palmitoyl tripeptide-38. The app's own note describes the ingredient as having "negligible systemic absorption" and says the modeled curve "does not really reflect how it works", which sits uneasily beside a listed bioavailability of 95%.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 4 h | No figure in the sources gathered |
| Bioavailability | 95% | No figure in the sources gathered |
| Time to peak | About 0.5 h | No figure in the sources gathered |
| Solubility and formulation | Not given by the app | Water soluble; recommended pH 3 to 9; added to the emulsion preferably between 25 and 50°C1 |
No skin-penetration study of palmitoyl tripeptide-38 itself was identified. A 2026 University of Nottingham study of three healthy female volunteers used secondary ion mass spectrometry on Pal-GHK and Pal-GQPR, peptides present in Matrixyl 3000, and reported both peptides "throughout every layer of the stratum corneum" with ion intensities that decreased with depth; two of the authors are employees of No7 Beauty Company, The Boots Group.4 That result concerns other peptides in a different product, and it does not describe palmitoyl tripeptide-38 or any blood level.4
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Sederma study, January to March 2010, in the Sederma brochure1 | Single-blind, split-face (crow's feet); forehead had no placebo side; manufacturer-run1 | 25 women, mean age 57 years (range 42 to 70)1 | 2% cream against placebo cream, twice a day for two months1 | Crow's feet: difference against placebo of -28.5% in the severity of the wrinkled appearance and -21% in wrinkle volume; forehead (no placebo side): wrinkle volume -31%1 |
| Lintner and colleagues, Journal of Cosmetic Dermatology 20203 | Open-label, before-and-after, no vehicle control; funded by Alumier3 | 35 women with photoaging, mean age 64 years3 | Serum with 15% vitamin C, tocopheryl acetate and 5 ppm palmitoyl tripeptide-38, once daily for 56 days3 | Day 28: periorbital relief Rz down a mean 9% (P = .0001), Rt 8% and Ra 8%, isotropy up a mean 4% in 68% of subjects; day 56: 9% decrease in redness; no adverse effects attributed to the serum3 |
| Sanz and colleagues (ISDIN), Journal of Cosmetic Dermatology 20165 | Clinical and instrumental evaluation of a multi-ingredient serum; the PubMed record names no comparator5 | 32 women with sensitive skin and crow's feet wrinkles5 | Serum applied to the face twice daily for 28 consecutive days5 | "relevant anti-wrinkle effect in 71% of the treated women", visible effects in 68% as soon as 7 days; authors from the serum maker's medical and innovation departments5 |
| Herndon and colleagues, Journal of Drugs in Dermatology 20156 | Open-label, multi-ingredient moisturizer including a peptide blend with palmitoyl tripeptide-386 | 37 women aged 35 to 60 who completed the study6 | Moisturizer twice daily; visits at baseline and weeks 4, 8 and 126 | Statistically significant improvement in all clinical grading parameters against baseline after 8 weeks; judged "mild and well tolerated"6 |
Sources in this part
The Herndon record lists the publication type "Research Support, Non-U.S. Gov't" but gives no funder statement, author affiliations or conflict-of-interest statement.6
None of the studies in the table tested palmitoyl tripeptide-38 alone against a vehicle in a published, independently funded trial that was identified.
Deeper analysis: the Sederma split-face study
The study is reported in the manufacturer's own brochure, not in a peer-reviewed paper, and the brochure gives its dates as January to March 2010 and the panel as 25 volunteers.1 The design was single-blind: the 2% cream went on one side of the face and the placebo cream on the other for the crow's feet, while on the forehead "only 2% MATRIXYL" was applied "for study compliance reasons", so the forehead figures have no placebo comparison.1 Volunteers were women with enough forehead and crow's feet lines, and they first used placebo on the whole face for a 15-day wash-out.1 On the forehead the brochure's synopsis lists a reduction of 31% in the volume of a main wrinkle with a p-value of 0.05, and its text says the volume "significantly diminishes by 31%".1 Forehead complexity fell 28% and maximum depth 16%, and the two trained technicians' clinical wrinkle score showed a significant improvement at two months.1 For the crow's feet the brochure tabulates the active-side change and the placebo-side change separately, and states a significant decrease in the severity of the wrinkled appearance of -28.5% against placebo.1 The brochure's text gives the crow's feet difference in mean depth as "-19% vs. placebo", whereas its synopsis lists a reduction in mean depth of -15%, and one set of impressions could not be used, so some crow's feet results are from 24 volunteers.1 The synopsis labels the -28.5% as a reduction in the surface occupied by deep wrinkles, while the text calls it a decrease in the severity of the wrinkled appearance.1 The brochure explains that volunteers applied less cream to the crow's feet than to the forehead, with "74% less was applied", which it offers as a reason for lower percentages there.1 On tolerance it states that the product "was well tolerated by the volunteers", and its toxicology list names a patch test in 10 volunteers, an HRIPT in 100 volunteers, a HET CAM and neutral red test, an Ames' test and expert certification, without giving their results in the text read.1 The brochure carries a Sederma copyright and a warranty disclaimer that the information is "given in good faith", and no limitations section, funder statement or author list appears in it; the study is by the ingredient's manufacturer.1
Deeper analysis: Lintner and colleagues, 2020
Lintner and colleagues (KAL'IDEES in Paris, True MediSpa and the University of Toronto) reported in the Journal of Cosmetic Dermatology in 2020 an open-label, 2-month, before-and-after study of 35 women with photoaging, mean age 64 years (range 49 to 74).3 The serum, EverActive C&E plus Peptide from Alumier Labs, contained l-ascorbic acid at 15% w/v, tocopheryl acetate and 5 ppm palmitoyl tripeptide-38, used once daily after cleansing for 56 days.3 Because the serum contained vitamins C and E as well, the results cannot be assigned to the peptide, and the authors themselves say that separating each ingredient "would be necessary to study all seven permutations".3 The authors name the missing control: "The absence of vehicle control might be considered to constitute a limitation of the study", and they judge a seven-arm design "unrealistic".3 On day 28, relief parameters Rz, Rt and Ra decreased by a mean of 9%, 8% and 8%, and the text reports improvements in rhytides and skin roughness over time in more than 70% of subjects.3 The isotropy measure rose a mean of 4% in 68% of subjects at day 28, while the day-56 row of the table shows a mean change of 0.3 (SEM 1.0), about 1%, with P below .05 and 55% of subjects counted as responders.3 The authors call the isotropy changes small, writing that "While the numerical change in percentage appears small, there is yet little basis for comparison and scaling of the isotropy parameter".3 Skin-tone photographs on days 0 and 56 showed a 9% decrease in redness and an 8% increase in homogeneity, and self-assessed wrinkle scores were logged every third day.3 For adverse events, subjects kept a daily log, and the paper states that the product "was well tolerated" and that "no adverse effects attributed to the serum were observed".3 In the product-characteristics questionnaire at day 56, 33% of subjects gave a negative rating for "not greasy" and for "not tacky".3 The study was funded by Alumier MD Laboratories, Toronto, and all three authors are consultants for Alumier Labs.3 The paper also cites a randomized vehicle-controlled clinical trial of the peptide that, it says, "confirmed the smoothing of forehead and crow's feet wrinkle features" in a preparation with 5 ppm palmitoyl tripeptide-38; that trial was not among the sources retrieved here, and the paper gives no design, size or funder for it.3
Doses reported in studies and on labels
The table lists concentrations as the sources give them; no regulator label for this cosmetic ingredient was identified.
| Source and setting | Preparation and concentration | Application and length | Reference |
|---|---|---|---|
| Sederma brochure, recommended concentration for use | 2% of the Matrixyl Synthe'6 product in a formulation | Not a dosing schedule | 1 |
| Sederma brochure, in vitro tests | 5 ppm Pal-KMO2K, stated as equivalent to 2% of the product | Cell and explant tests | 1 |
| Sederma brochure, 25 women, split-face | 2% cream against placebo cream | Twice a day for two months | 1 |
| Lintner 2020, 35 women | Serum with 5 ppm palmitoyl tripeptide-38 plus 15% vitamin C and tocopheryl acetate | Once daily for 56 days | 3 |
| Sanz 2016, 32 women | Serum with palmitoyl tripeptide-38 among other actives; peptide concentration not given in the record | Twice daily for 28 consecutive days | 5 |
| Herndon 2015, 37 women | Moisturizer with a peptide blend including palmitoyl tripeptide-38; concentration not given in the record | Twice daily, 12 weeks | 6 |
| App's figure | 2 to 4% | Not applicable | Not applicable |
Sources in this part
The app's upper figure of 4% is higher than the 2% concentration the brochure recommends, and none of the sources gathered reports a 4% use level.1
Side effects reported
Sources in this part
The Sederma brochure states "The product was well tolerated by the volunteers" for its 25-woman study.1 The Lintner paper reports "no adverse effects attributed to the serum" in 35 women over 56 days, with a daily log of adverse effects or undesirable sensations.3 Herndon and colleagues write that the moisturizer was "judged to be mild and well tolerated" and that several tolerability parameters showed no statistically significant increase over baseline, in a product that contains other ingredients.6 None of these records reports a rate of irritation or allergy for palmitoyl tripeptide-38 alone, and the brochure lists patch-test, HRIPT and HET CAM tests without results in the text read.1
What is not known
Sources in this part
- No peer-reviewed, vehicle-controlled trial of palmitoyl tripeptide-38 alone was identified in PubMed or ClinicalTrials.gov.
- The half-life, bioavailability, time to peak and blood level of the peptide in people are not reported in the sources gathered, so the app's figures of 4 hours, 95% and 0.5 hours have no reported figure from a source beside them.
- Whether the matrix-molecule increases measured in cells and explants occur in the skin of people who apply the cream is not shown by the studies read.
- No dedicated safety assessment of palmitoyl tripeptide-38 by a regulator or an expert panel was identified by a web search, and a 2013 review of palmitoyl oligopeptides that a secondary site mentions was not confirmed to cover it.
- The brochure's study has no stated funder statement, author list or limitations section, and the independently published studies are funded by or tied to the makers of the serums tested.1,3,5
Frequently asked questions
Sources in this part
What is Matrixyl Synthe'6?
What is the INCI name of Matrixyl Synthe'6?
A distributor lists the INCI names as Glycerin, Aqua, Hydroxypropyl Cyclodextrin, Palmitoyl Tripeptide-38.2
What is the half-life of Matrixyl Synthe'6?
None of the sources gathered gives a half-life for palmitoyl tripeptide-38, and the app lists 4 hours. The app's own note says systemic absorption is negligible and the modeled curve does not reflect how the ingredient works.
What is the bioavailability of Matrixyl Synthe'6?
The app lists 95%, and none of the sources gathered reports a bioavailability figure for palmitoyl tripeptide-38.
What concentration of Matrixyl Synthe'6 is used in studies and by the manufacturer?
Does Matrixyl Synthe'6 reduce wrinkles in studies?
In the manufacturer's split-face study of 25 women, crow's feet wrinkle volume differed by -21% against placebo, with a stated p-value below 0.05.1 The three journal-published studies tested multi-ingredient products, and the Lintner authors write that "The absence of vehicle control might be considered to constitute a limitation of the study"; that study was funded by Alumier MD Laboratories and its authors are consultants for Alumier Labs.3
Does Matrixyl Synthe'6 increase collagen?
What side effects are reported for Matrixyl Synthe'6?
The Lintner paper reports no adverse effects attributed to the serum in 35 women over 56 days.3 The manufacturer states its product "was well tolerated by the volunteers" in a 25-woman study.1 Herndon and colleagues describe a multi-ingredient moisturizer containing a peptide blend that includes palmitoyl tripeptide-38 as "judged to be mild and well tolerated", with no statistically significant increase in several tolerability scores over baseline.6
Guides, tools and comparisons
References
- Sederma (Croda). Matrixyl synthe'6 technical brochure, 2015 (copy hosted by a retailer). Sederma technical brochure
- Brenntag. Matrixyl Synthe'6 product page (Brazil, English), accessed 16 November 2026. Brenntag product page
- Lintner K, Gerstein F, Solish N. A serum containing vitamins C & E and a matrix-repair tripeptide reduces facial signs of aging as evidenced by Primos analysis and frequently repeated auto-perception. J Cosmet Dermatol 2020;19:3262-3269. PMID 33103342
- Trzaska AH, et al. Permeation behaviour of cosmetic actives into the human stratum corneum. Int J Pharm 2026;705:127447. PMID 42790608
- Sanz MT, et al. Biorevitalizing effect of a novel facial serum containing apple stem cell extract, pro-collagen lipopeptide, creatine, and urea on skin aging signs. J Cosmet Dermatol 2016;15:24-30. PMID 26424007
- Herndon JH, et al. An Open Label Clinical Trial of a Multi-Ingredient Anti-Aging Moisturizer Designed to Improve the Appearance of Facial Skin. J Drugs Dermatol 2015;14:699-704. PMID 26151786